Archive · 8 Jan 2026
India's DengiAll Dengue Vaccine Nears Completion
India has been working on a vaccine called DengiAll for 17 years to fight dengue, a disease that affects many people in tropical areas.
The vaccine is now in its final testing phase with over 10,000 volunteers.
It aims to protect against all four types of the dengue virus.
Early tests showed it works well, and if the final tests are successful, it could be approved soon.
This vaccine could help millions of people stay safe from dengue.
India's first indigenous dengue vaccine, DengiAll, has completed or is nearing completion of Phase-III trials.
The vaccine is designed to protect against all four dengue virus serotypes in a single shot.
Phase-III trials involved over 10,000 volunteers across nearly 20 sites in India.
Early trials showed protection levels of 77–82% against all four serotypes.
If the interim analysis is positive, Panacea Biotec could seek approval before the full two-year follow-up period ends.
- Who
- Panacea Biotec, Indian Council of Medical Research (ICMR)
- What
- Development of India's first indigenous dengue vaccine, DengiAll
- When
- Phase-III trials began in August 2024
- Where
- Multiple sites across India
- Why
- To protect against all four dengue virus serotypes and reduce the global burden of dengue
- Vaccine Name
- DengiAll
- Developer
- Panacea Biotec
- Supporting Organization
- Indian Council of Medical Research (ICMR)
- Research Duration
- 17 years
- Trial Phase
- Phase-III
- Number of Participants
- 10,000+
- Protection Levels
- 77–82% against all four serotypes
